One-Stop care may boost HIV and hep c treatment in drug users

NCT ID NCT03981445

Ongoing Prevention Sponsor: Columbia University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether providing HIV prevention (PrEP) and hepatitis C treatment together at one location works better than sending patients to separate clinics. About 446 people who inject drugs will be randomly assigned to either on-site integrated care or off-site referrals with patient navigation. The goal is to see which approach leads to better PrEP adherence and higher hepatitis C cure rates.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: patient navigation (behavioral intervention)
What this could lead to: If successful, this could show that offering HIV prevention and HCV treatment in one place works better than sending patients to different clinics, improving health outcomes for people who inject drugs.
What could go wrong: This is a behavioral study, not a drug trial, so results depend on patient engagement and local resources. The findings may not apply to all communities or healthcare systems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HCV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatitis C virus infection opioid abuse HIV infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HCV HIV PREVENTION INTRAVENOUS DRUG USAGE OPIOID USE

Contacts and locations

Locations

Columbia University Irving Medical Center

New York, New York, 10032, United States
Miami

Miami, Florida, 33136, United States
Montreal

Montreal, Quebec, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.